KMDA or TECH: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Kamada (KMDA) and Techne (TECH). But which of these two stocks presents investors with the better value opportunity right now?

Zacks Investment Research • Feb 17, 2026

Kamada (KMDA) Soars 8.1%: Is Further Upside Left in the Stock?

Kamada (KMDA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Investment Research • Jan 27, 2026

Kamada Announces a $10-$14 Million Extension of Canadian Supply Tender

REHOVOT, Israel, and HOBOKEN, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that the Company has been awarded an extension of an existing tender from the Canadian Blood Services (CBS) for the supply of four specialty plasma-derived  products, WINRHO®, HEPAGAM®, CYTOGAM®, and VARIZIG®, for an additional two years. Valued at a range of $10-$14 million, the award secures ongoing sales of those products in the Canadian market between Q2-26 and Q1-28. The four commercial products are approved by Health Canada and the U.S. Food and Drug Administration (FDA). CBS manages the Canadian supply of blood products for all Canadian provinces and territories, excluding Quebec.

GlobeNewsWire • Dec 18, 2025

Kamada Shuts Down Phase 3 Study For Genetic Condition, Reiterates Outlook

Kamada Ltd. (NASDAQ: KMDA) on Monday said it will discontinue its Phase 3 InnovAATe trial of Inhaled AAT for Alpha-1 Antitrypsin Deficiency (AATD).

Benzinga • Dec 8, 2025

Kamada Ltd. (KMDA) Discusses Discontinuation of Phase 3 Inhaled AAT Clinical Trial and Financial Outlook Transcript

Kamada Ltd. (KMDA) Discusses Discontinuation of Phase 3 Inhaled AAT Clinical Trial and Financial Outlook Transcript

Seeking Alpha • Dec 8, 2025

Kamada (KMDA) is an Incredible Growth Stock: 3 Reasons Why

Kamada (KMDA) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Investment Research • Nov 11, 2025

Kamada Ltd. (KMDA) Q3 2025 Earnings Call Transcript

Kamada Ltd. ( KMDA ) Q3 2025 Earnings Call November 10, 2025 8:30 AM EST Company Participants Amir London - Chief Executive Officer Chaime Orlev - Chief Financial Officer Conference Call Participants Brian Ritchie - Lifesci Advisors, LLC Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division James Sidoti - Sidoti & Company, LLC Presentation Operator Good morning.

Seeking Alpha • Nov 10, 2025

Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth

REHOVOT, Israel, and HOBOKEN, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced financial results for the three months and nine months ended September 30, 2025.

GlobeNewsWire • Nov 10, 2025

Kamada (KMDA) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Kamada (KMDA) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Investment Research • Nov 10, 2025

Kamada (KMDA) Misses Q3 Earnings Estimates

Kamada (KMDA) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.07 per share a year ago.

Zacks Investment Research • Nov 10, 2025